Hormonal
Chronic pharmacotherapy with GLP-1 receptor agonists (semaglutide 2.4 mg) and dual agonists (tirzepatide 10-15 mg) produces significantly greater and more sustained weight loss than behavioral interventions alone by neutralizing counter-regulatory physiological mechanisms.
If you have obesity, lifestyle changes alone often fail long-term because your body fights back by increasing hunger hormones. New medications like semaglutide (weekly injection) or tirzepatide (weekly injection) work by overriding this biological defense, allowing for significantly greater weight loss (often >15%) than diet and exercise alone. These are intended for chronic use to maintain results.
Second-generation AOMs produce weight losses that are larger and more sustained than behavioral obesity treatment (18). These AOMs appear to neutralize the powerful counter-regulatory mechanisms that occur in a weight-reduced state.
Why this rating
Based on multiple large-scale Phase 3 RCTs (STEP 1-5, SURMOUNT 1-4) with consistent, high-magnitude results.
Source
Evolving Approaches for Pharmacological Therapy of Obesity
Ariana M. Chao et al. · The Annual Review of Pharmacology and Toxicology · 2024
DOI 10.1146/annurev-pharmtox-031124-101146
More from this paper
- Tirzepatide (10-15 mg) produces greater mean weight loss than semaglutide (2.4 mg) in head-to-head comparisons, achieving reductions of up to 20.9%.Strong
- Discontinuation of GLP-1 based therapies leads to significant weight regain, indicating that obesity requires chronic management rather than short-term treatment.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →